Business Context and Reporting Period
This Form 8-K Current Report was filed by IRIDEX Corporation (Nasdaq: IRIX) on August 27, 2026. The filing addresses a regulatory compliance issue regarding the continued listing of the Company's common stock on the Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on stock listing compliance.
Material Changes and Events
- Non-Compliance Notice: The Company received a notification from Nasdaq stating that its common stock's minimum bid price has been below the $1.00 per share requirement for the last 30 consecutive business days.
- Regulatory Basis: The deficiency violates Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Requirement).
- Current Status: The stock remains listed and traded on Nasdaq during the cure period.
Outlook, Management Commentary, and Risks
- Cure Period: The Company has 180 calendar days (until February 23, 2027) to regain compliance. Compliance is achieved if the closing bid price is at least $1.00 per share for 10 consecutive business days.
- Contingency Plan: If the Company fails to regain compliance by the end of the initial period, it may qualify for an additional 180-day extension. This requires meeting all other initial listing standards (except the bid price) and potentially effecting a reverse stock split.
- Delisting Risk: Failure to qualify for or achieve compliance during the second period will result in delisting notification, subject to appeal.
- Operational Impact: Management states the non-compliance has no immediate impact on ongoing business operations or SEC reporting requirements.
- Forward-Looking Statements: The Company cautions that there is no assurance it will regain compliance or maintain listing status.
Investor Verification Checklist
- Verify the current closing bid price of IRIX stock to assess proximity to the $1.00 threshold.
- Monitor future announcements regarding the potential implementation of a reverse stock split.
- Review the Company's most recent 10-K or 10-Q filings for underlying financial performance data not included in this 8-K.
- Track the deadline of February 23, 2027, for the initial cure period expiration.